MedTrace Logo

Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital

NCT04577989 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 270

Last updated 2023-02-01

No results posted yet for this study

Summary

This study is to investigate the recent epidemiological trends and the treatment outcome in terms of the length of hospital stay, the relevant renal and neurological side effects, risk factors for developing these side effects, the selection of more resistant pathogens under therapy as well as the incidence of Clostridium difficile infections under treatment.

Conditions

  • Infection With AmpC Beta-lactamase Producing Enterobacterales

Interventions

OTHER

data collection

data collection for treatment strategies (cefepime vs. piperacillin/tazobactam vs. carbapenems) of infections caused by AmpC beta-lactamase producing Enterobacterales for the period January 1st , 2015 until July 31st , 2020.

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Sarah Tschudin Sutter, Prof. Dr. med. · Division of Infectious Disease and Hospital Epidemiology,University Hospital Basel

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-14
Primary Completion
2022-12-19
Completion
2022-12-19

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04577989 on ClinicalTrials.gov